Table 9.
Effectiveness of ARV program, the Lighthouse Lilongwe and MSF Thyolo
| Indicator | Lighthouse, Lilongwe | Thyolo DH |
| Hosseinipour et al86 | ||
| References | Neuhann et al87 | Harries et al89 |
| Hosseinipour et al88 | ||
| Description of cohort | ||
| Jan–Jun 2003 (ref 86) | ||
| Period | Jul–Dec 2003 (ref 87) | April–Sep 2003 |
| Jan–Jul 2003 (ref 88) | ||
| 179 (ref 86) | ||
| Number of patients | 753 (ref 87) | 220 |
| 141 (ref 88) | ||
| WHO stage 3 or 4 | 62% (ref 88) | Not reported |
| Women | 52% (ref 88) | Not reported |
| CD4 before ART (cells/µl) | 50 (ref 88) | Not reported |
| Fee | For medication | Free |
| Process | ||
| Alive and on ARV | 64% at 6 months (ref 88) | 90% after 3–6 months |
| Lost to follow-up | 7% at 6 months(ref 88) | 0% after 3–6 months |
| Stopped therapy | 3% at 6 months (ref 88) | 4% after 3–6 months |
| On alternative 1st line therapy | 1% (ref 88) | 4% |
| On 2nd line therapy | 0% (ref 88) | 0% |
| Adherent ≥ 95% | 95% (ref 88) | 99% |
| Outcome | ||
| Median change in bodyweight (kg) | 5.7 (ref 88) | Not reported |
| Median change in CD4 count (cells/µl) | 92 (ref 88) | Not reported |
| HIV RNA below 400 copies | 79% (ref 88) | Not reported |
| Resumed normal daily activity | 72% (ref 87) | 88% |
| Early mortality (≤3 months) | 25% (ref 86) | Not reported |
| Total mortality | 27% (ref 88) | 6% |
| Side effects reported | 32% (ref 87)* | 14% |
*
Study only reported on neuropathic pain